Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 30, 2025Journal of Clinical MedicineOpen Access

Neurofibromatosis Type 1 and MEK Inhibition: A Comprehensive Review with Focus on Selumetinib Therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

GIGeorge ImatakaSKShigeko KuwashimaSHShujiro Hayashi

Discussion

Loading...

Member takes

Overview

Comprehensive review highlights selumetinib's efficacy for tumor shrinkage in neurofibromatosis type 1, suggesting its potential medical benefits.

Key Points

  • Neurofibromatosis type 1 (NF1) poses a risk for malignancies and lacks effective medical therapies for tumor shrinkage.
  • MEK inhibitors like selumetinib show promise in treating severe NF1 manifestations, with demonstrated efficacy in preclinical studies.
  • A detailed case study illustrates the clinical application and challenges of selumetinib therapy in a patient with NF1.
  • Insights from this review may guide real-world clinical practices for managing NF1 using targeted treatment approaches.

Cite This Study

Imataka et al. (2025) studied this question.

synapsesocial.com/papers/689a0945e6551bb0af8cee00https://doi.org/10.3390/jcm14145071
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1MEK Inhibitors for Neurofibromatosis Type 1-Associated Central and Peripheral Nervous System Tumors2024
  2. 2Targeted Therapies in Neurofibromatosis Type 12025
  3. 3CTP-14. Treatment with MEK inhibitors in patients with low-grade gliomas in Neurofibromatosis type 1: a preliminary report2025
  4. 4Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma2024 · 29 citations
  5. 5NFS-27. SELUMETINIB FOR SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS IN NEUROFIBROMATOSIS TYPE 1: A SINGLE-INSTITUTION EXPERIENCE2024 · 1 citations